PT - JOURNAL ARTICLE AU - M. Taquet AU - J.R. Geddes AU - M. Husain AU - S. Luciano AU - P.J. Harrison TI - Six-month Neurological and Psychiatric Outcomes in 236,379 Survivors of COVID-19 AID - 10.1101/2021.01.16.21249950 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.16.21249950 4099 - http://medrxiv.org/content/early/2021/01/24/2021.01.16.21249950.short 4100 - http://medrxiv.org/content/early/2021/01/24/2021.01.16.21249950.full AB - Background Neurological and psychiatric sequelae of COVID-19 have been reported, but there are limited data on incidence rates and relative risks.Methods Using retrospective cohort studies and time-to-event analysis, we estimated the incidence of ICD-10 diagnoses in the 6 months after a confirmed diagnosis of COVID-19: intracranial haemorrhage; ischaemic stroke; Parkinsonism; Guillain-Barré syndrome; nerve/nerve root/plexus disorders; myoneural/muscle disease; encephalitis; dementia; mood, anxiety, and psychotic disorders; substance misuse; and insomnia. Data were obtained from the TriNetX electronic health records network (over 81 million patients). We compared incidences with those in propensity score-matched cohorts of patients with influenza or other respiratory infections using a Cox model. We investigated the effect on incidence estimates of COVID-19 severity, as proxied by hospitalization and encephalopathy (including delirium and related disorders).Findings 236,379 patients survived a confirmed diagnosis of COVID-19. Among them, the estimated incidence of neurological or psychiatric sequelae at 6 months was 33.6%, with 12.8% receiving their first such diagnosis. Most diagnostic categories were commoner after COVID-19 than after influenza or other respiratory infections (hazard ratios from 1.21 to 5.28), including stroke, intracranial haemorrhage, dementia, and psychotic disorders. Findings were equivocal for Parkinsonism and Guillain-Barré syndrome. Amongst COVID-19 cases, incidences and hazard ratios for most disorders were higher in patients who had been hospitalized, and markedly so in those who had experienced encephalopathy. Results were robust to sensitivity analyses, including comparisons against an additional four index health events.Interpretation The study provides evidence for substantial neurological and psychiatric morbidity following COVID-19 infection. Risks were greatest in, but not limited to, those who had severe COVID-19. The information can help in service planning and identification of research priorities.Funding National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre.Competing Interest StatementSL is an employee of TriNetX Inc.Funding StatementNational Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:TriNetX has a waiver from the Western Institutional Review Board since only aggregated counts and summaries of de-identified information are used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe TriNetX system returned the results of these analyses as csv files which were downloaded and archived. Data presented in this paper and the Appendix can be freely accessed at [URL to be added on publication]. Additionally, TriNetX will grant access to researchers if they have a specific concern (via the third-party agreement option).